Ovid Therapeutics Inc. (FRA:1OT)
Germany · Delayed Price · Currency is EUR | Market Cap | 376.71M +282.1% |
| Revenue (ttm) | 1.39M -76.2% |
| Net Income | -30.18M |
| EPS | -0.25 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 50 |
| Open | 2.060 |
| Previous Close | 2.140 |
| Day's Range | 2.060 - 2.060 |
| 52-Week Range | 0.970 - 2.520 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About Ovid Therapeutics
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's d... [Read more]
Financial Performance
In 2025, Ovid Therapeutics's revenue was $7.25 million, an increase of 1181.27% compared to the previous year's $566,000. Losses were -$17.14 million, -34.01% less than in 2024.
Financial numbers in USD Financial StatementsNews
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the...
Ovid Therapeutics initiated with an Outperform at Wolfe Research
Wolfe Research initiated coverage of Ovid Therapeutics (OVID) with an Outperform rating and $5 price target
Ovid Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Imogen Mansfield initiated coverage of Ovid Therapeutics (OVID) with an Overweight rating. The firm’s DCF valuation implies roughly $6/share, over 150% upside, supported by i...
Ovid Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Imogen Mansfield initiated coverage of Ovid Therapeutics (OVID) with an Overweight rating.
Ovid Therapeutics management to meet with B. Riley
Meeting to be held in Los Angeles on October 14 hosted by B. Riley.
Guggenheim starts Ovid Therapeutics with a Buy on OV329 potential
As previously reported, Guggenheim initiated coverage of Ovid Therapeutics (OVID) with a Buy rating and $7 price target OV329, the company’s lead asset, is a next-generation GABA-AT inhibitor engineer...
Ovid Therapeutics initiated with a Buy at Guggenheim
Guggenheim analyst Delma Caiati initiated coverage of Ovid Therapeutics (OVID) with a Buy rating and $7 price target
Ovid Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Novel therapies targeting neural hyperexcitability are advancing, with OV329 showing strong safety and efficacy in epilepsy and a billion-dollar market potential. The KCC2 portfolio, including a first-in-class oral activator, is progressing toward key milestones in schizophrenia and other CNS disorders.
Ovid Therapeutics price target raised to $5 from $4 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Ovid Therapeutics (OVID) to $5 from $4 and keeps a Buy rating on the shares. The firm cites the…
Ovid Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Key clinical programs include a first-in-class KCC2 activator and a next-gen GABA-AT inhibitor, with multiple proof-of-concept and biomarker readouts expected in the next 6–24 months. The pipeline targets major unmet needs in epilepsy, psychoses, and rare pediatric epilepsies, with significant market and scientific differentiation.
Ovid Therapeutics price target raised to $8 from $7 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan raised the firm’s price target on Ovid Therapeutics (OVID) to $8 from $7 and keeps a Buy rating on the shares. The firm is adjusting…
Ovid Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant u...
Ovid Therapeutics reports Q2 EPS (8c), consensus (10c)
Reports Q2 revenue $733,000 vs. $6.27M last year. “Ovid is focused on the execution of multiple near-term clinical, proof-of-concept studies across our differentiated pipeline,” said Meg Alexander, Pr...
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant un...
Ovid Therapeutics Slides: Corporate presentation
Ovid Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
Ovid Therapeutics Quarterly report: Q2 2026
Ovid Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
Ovid Therapeutics Earnings release: Q2 2026
Ovid Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Ovid Therapeutics price target raised to $9 from $7 at Oppenheimer
Oppenheimer raised the firm’s price target on Ovid Therapeutics (OVID) to $9 from $7 and keeps an Outperform rating on the shares. The firm notes Ovid currently trades primarily on…
Ovid Therapeutics CFO Jeffrey Rona to step down, Charles Carter to succeed
Ovid Therapeutics (OVID) announced several strategic appointments. Kevin Norrett will join Ovid as chief business officer to spearhead business and corporate development functions as well as strategic...
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant un...
Ovid Therapeutics Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference
The company is advancing a diversified pipeline of small molecule therapies for neurological and neuropsychiatric disorders, with OV329 and OV4071 as lead assets. Key clinical milestones are expected in the next 6–24 months, supported by strong financial runway and a strategic approach to partnerships.
Ovid Therapeutics Transcript: AGM 2026
The meeting covered director election, executive compensation, and auditor ratification, with all proposals approved. No shareholder questions were raised, and quorum was established with 75.7% of shares represented.
Ovid Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant un...
Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant un...
Ovid Therapeutics price target raised to $7 from $5 at Roth Capital
Roth Capital raised the firm’s price target on Ovid Therapeutics (OVID) to $7 from $5 and keeps a Buy rating on the shares. The firm is updating its discount cash…